FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: GlobeNewswire
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the FirstGene® Multiple Prenatal Screen in Clinical Chemistry. The study showed that each component of the test had exceptional sensitivity and specificity. Titled “Simultaneous prenatal cfDNA screening of aneuploidy, recessive single-gene conditions, and fetomaternal blood compatibility,” the study used nearly 500 samples to assess the multiple components of the FirstGene screen, including fetal aneuploidy testing, RhD compatibility, and recessive condition status in the pregnant person and fetus, including 19 prevalent and severe conditions. It found that every component of the test had =98.2% analytical sensitivity and =99.0% analytical specificity. “The FirstGene screen was designed as an integrated, multifaceted solution that analyzes key aspects of the maternal and fe
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026GlobeNewswire
- Myriad Advances MRD Commercialization Timeline, Bolstered by New Study DataGlobeNewswire
- 2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics (NASDAQ:MYGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
MYGN
Earnings
- 11/3/25 - Beat
MYGN
Sec Filings
- 2/11/26 - Form SCHEDULE
- 2/9/26 - Form SCHEDULE
- 2/3/26 - Form 4
- MYGN's page on the SEC website